Cannara BiotechTSX:LOVE +5.00%92 EBITDA Margin % is 17.02% as of Feb. 2026, which is 11% below its 10-year median of 19.18. GuruFocus rates TSX:LOVE with a GF Score™ of 92/100 and a GF Value™ of C$1.68 (Fairly Valued). The stock has 4 warning signs investors should review. Among 955 Drug Manufacturers companies, Cannara Biotech ranks better than 71.94% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cannara Biotech's EBITDA for the
three
months ended in Feb. 2026 was C$4.6 Mil. Cannara Biotech's Revenue for the
three
months ended in Feb. 2026 was C$27.2 Mil. Therefore, Cannara Biotech's EBITDA margin for the quarter that ended in Feb. 2026 was 17.02%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cannara Biotech EBITDA Margin % Related Terms
Cannara Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cannara Biotech (TSX:LOVE) has a EBITDA Margin % of 17.02% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannara Biotech and its competitors. This is 11% below median its historical median of 19.18. According to the industry distribution chart, Cannara Biotech ranks #268 out of 955 companies in the Drug Manufacturers industry, placing it in the top 28.1%.
Is Cannara Biotech's EBITDA Margin % too high?
Cannara Biotech's current EBITDA Margin % of 17.02% is 11% below median its 10-year median of 19.18. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Cannara Biotech's value of 17.02% is 36.8% above this industry median. Based on the distribution chart, Cannara Biotech ranks #268 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Cannara Biotech has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #268 out of 955 companies for EBITDA Margin %. This puts Cannara Biotech in the upper half of its industry. The industry median EBITDA Margin % is 12.44. Cannara Biotech's value of 17.02% is 36.8% above this benchmark. While the company's 10-year median is 19.18 vs. the industry median of 12.44, Cannara Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current EBITDA Margin % of 17.02% is 36.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current EBITDA Margin % is 17.02%, which is 11% below median its own 10-year median of 19.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (TSX:LOVE) is currently considered Fairly Valued. The stock's GF Value™ is C$1.68, compared to a current price of C$1.68 — trading right at its estimated fair value. The current EBITDA Margin % is 17.02%, which is 11% below median its 10-year median of 19.18 and 36.8% above the Drug Manufacturers industry median of 12.44. Cannara Biotech's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cannara Biotech (TSX:LOVE), the current EBITDA Margin % is 17.02% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (TSX:LOVE) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be undervalued.
The current stock price of C$1.68 is trading 0% below its estimated GF Value™ of C$1.68.
GuruFocus considers Cannara Biotech to be Fairly Valued.
Key valuation signals for TSX:LOVE:
EBITDA Margin %: 17.02% (11% below median its 10-year median of 19.18)
GF Value™: C$1.68 vs. price of C$1.68 (0% below fair value)
Industry Position: 36.8% above the Drug Manufacturers median (#268 of 955)
No single metric tells the full story. See the TSX:LOVE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
92GF Score
Get the complete analysis for TSX:LOVE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:LOVE has been successfully added to your 
